Literature DB >> 17982677

Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion.

Severine Van Slambrouck1, Clara Grijelmo, Olivier De Wever, Erik Bruyneel, Shahin Emami, Christian Gespach, Wim F A Steelant.   

Abstract

Increased src tyrosine kinase expression and activity has been associated with colon cancer cell invasion and survival. Several signaling pathways are involved in the oncogenic activation of src during the adenoma to carcinoma progression and cellular invasion. In the present study, the synthetic ether lipid analog ET-18-OMe was shown to promote invasion of HCT-8/S11 colon cancer cells into collagen type I through the concomitant activation of src by phosphorylation at Tyr416 (5-30 min) in alpha1-integrin immunoprecipitates containing the integrin binding proteins talin and paxillin, as well as the phoshorylated and activated forms of focal adhesion kinase (FAK) at Tyr397 (a FAK kinase activation signal), Tyr576 and Tyr861. This was associated with the lateral redistribution of alpha1-integrins in focal aggregates and persistent activation of the p130Cas/JNK pathways at 5-30 min, with the subsequent induction and activation of the matrix metalloproteinases MMP-2 and MMP-9 (2-12 h). These activated molecular scaffolds and signaling cascades were not observed in immunoprecipitates of alpha2- and beta1-integrins, and tetraspanin CD9, an invasion and metastasis suppressor linked to integrins and FAK signaling. Our data demonstrate that the lateral redistribution and clustering of alpha1-integrins results in the recruitment of the FAK/src motility-promoting signaling complex involved in cancer cell invasion. Disruption of this proinvasive pathway was accomplished by the dominant negative mutant of src (K295R, kinase dead), src pharmacological inhibitor (PP1) and alpha1-integrin function blocking antibodies. These findings support the notion that the alpha1-integrin- and src-dependent signalosome is a relevant therapeutic target against tumor progression in colon cancer patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982677

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  34 in total

1.  Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer.

Authors:  Severine Van Slambrouck; Aaron R Jenkins; Anntherese E Romero; Wim F A Steelant
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

2.  Functional significance of VEGFR-2 on ovarian cancer cells.

Authors:  Whitney A Spannuth; Alpa M Nick; Nicholas B Jennings; Guillermo N Armaiz-Pena; Lingegowda S Mangala; Christopher G Danes; Yvonne G Lin; William M Merritt; Premal H Thaker; Aparna A Kamat; Liz Y Han; James R Tonra; Robert L Coleman; Lee M Ellis; Anil K Sood
Journal:  Int J Cancer       Date:  2009-03-01       Impact factor: 7.396

3.  Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts.

Authors:  Jean Y J Wang; Christian Gespach; Olivier DE Wever; Joëlle Sobczak-Thépot; Anne-Sophie Vercoutter-Edouart; Jean-Claude Michalski; Radia Ouelaa-Benslama; Dwayne G Stupack; Marc Bracke; Shahin Emami
Journal:  Int J Oncol       Date:  2011-05-09       Impact factor: 5.650

Review 4.  The role of FAK in tumor metabolism and therapy.

Authors:  Jianliang Zhang; Steven N Hochwald
Journal:  Pharmacol Ther       Date:  2013-12-09       Impact factor: 12.310

5.  Abnormal cell properties and down-regulated FAK-Src complex signaling in B lymphoblasts of autistic subjects.

Authors:  Hongen Wei; Mazhar Malik; Ashfaq M Sheikh; George Merz; W Ted Brown; Xiaohong Li
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

Review 6.  Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.

Authors:  Duangmani Thanapprapasr; Wei Hu; Anil K Sood; Robert L Coleman
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  Targeting tumor cell motility to prevent metastasis.

Authors:  Trenis D Palmer; William J Ashby; John D Lewis; Andries Zijlstra
Journal:  Adv Drug Deliv Rev       Date:  2011-06-02       Impact factor: 15.470

8.  NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells.

Authors:  Takeshi Kubota; Hiroaki Taiyoh; Atsushi Matsumura; Yasutoshi Murayama; Daisuke Ichikawa; Kazuma Okamoto; Hitoshi Fujiwara; Hisashi Ikoma; Masayoshi Nakanishi; Shojiro Kikuchi; Chouhei Sakakura; Toshiya Ochiai; Yukihito Kokuba; Hiroki Taniguchi; Teruhisa Sonoyama; Kunio Matsumoto; Toshikazu Nakamura; Eigo Otsuji
Journal:  Clin Exp Metastasis       Date:  2009-02-21       Impact factor: 5.150

Review 9.  Progress in researches about focal adhesion kinase in gastrointestinal tract.

Authors:  Hui-Fang Hao; Yoshio Naomoto; Xiao-Hong Bao; Nobuyuki Watanabe; Kazufumi Sakurama; Kazuhiro Noma; Yasuko Tomono; Takuya Fukazawa; Yasuhiro Shirakawa; Tomoki Yamatsuji; Junji Matsuoka; Munenori Takaoka
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

10.  N-terminal and C-terminal heparin-binding domain polypeptides derived from fibronectin reduce adhesion and invasion of liver cancer cells.

Authors:  Nan-Hong Tang; Yan-Lin Chen; Xiao-Qian Wang; Xiu-Jin Li; Yong Wu; Qi-Lian Zou; Yuan-Zhong Chen
Journal:  BMC Cancer       Date:  2010-10-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.